Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
Main Authors: | Benoit Souchet, Mickael Audrain, Baptiste Billoir, Laurent Lecanu, Satoru Tada, Jérôme Braudeau |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Neural Regeneration Research |
Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2018;volume=13;issue=2;spage=224;epage=225;aulast=Souchet |
Similar Items
-
Biological Diagnosis of Alzheimer’s Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?
by: Benoît Souchet, et al.
Published: (2023-12-01) -
Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice
by: Benoît Souchet, et al.
Published: (2019-03-01) -
Dialoguing with the silent researcher: Rethinking the role of the transcriptionist in qualitative research
by: Heather Hurst, et al.
Published: (2019-07-01) -
Oxidative stress-mediated brain dehydroepiandrosterone (DHEA) formation in Alzheimer’s disease diagnosis
by: Geogres eRammouz, et al.
Published: (2011-11-01) -
Rethinking Alzheimer’s disease
by: Alexandre de Mendonça
Published: (2012-03-01)